Plant Engineering New Order for Bilfinger: Austrian Division Builds Pharmaceutical Plant in China
Bilfinger Industrietechnik Salzburg, a subsidiary of Bilfinger Industrial Technologies, will construct a glycoprotein production site near Beijing, PR China. The company will deliver the cell culture and fermentation systems for a Chinese pharmaceutical partner, speakers explained.
Salzburg/Austria – "This order is a valuable reference for our subsidiary Bilfinger Industrietechnik Salzburg for future operations in the booming Chinese market", commented CEO Gerhard Schmidt the € 4 million order. "We see the order as evidence that in the processing of international systems delivery transactions carried out to date, our company has been able to consistently satisfy its clients", Tobias Eitel, Executive Manager at Bilfinger Industrietechnik Salzburg, added.
The manufacture of the reactor will, for the most part, be carried out in two steps. Step one calls for the complete manufacture of the system including functional testing in the internal production facilities in Salzburg. Afterwards, the system will be packed for transport on large skids, transported to the Beijing site and reassembled there.
The fermentation system for Eastern Biotech consists of a media application tank in which the culture solution is produced. The cultivation of sensitive mammalian cells is carried out in seed, intermediate and production bioreactors. The antibodies that are to be produced are in the fermentation solution that has been freed from cells. This solution is subsequently collected in a cooled harvest container and prepared for further purification. A cleaning in place (CIP) system ensures the automatic cleaning of all system components without the need for the operator to intervene.